Test Price
2,800 AED✅ Home Collection Available
ELAC2 Gene Prostate Cancer Susceptibility Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary telephonic post‑test genetic counselling and result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced NGS panel sequences the entire ELAC2 gene to identify pathogenic variants associated with autosomal dominant hereditary prostate cancer type 2. The test empowers clinicians to stratify lifetime risk and implement tailored early‑detection strategies.
| Feature | Our Test (DHA‑Endorsed) | Closest Alternative |
|---|---|---|
| Methodology | Full‑gene NGS (Illumina NovaSeq) with Sanger confirmation | Single‑site genotyping or limited exome panels |
| Turnaround Time | 3 – 4 Weeks | 4 – 6 Weeks |
| Pre‑test Genetic Counselling | Included (pedigree chart & risk assessment) | Often an additional cost |
| Result Interpretation | Board‑certified genetic counsellors & medical geneticist | Automated report only |
Physician Insight & Safety Protocols
“An ELAC2 genetic test reveals susceptibility, not a diagnosis. A positive result must be correlated with family pedigree, digital rectal examination, and PSA kinetics—never interpreted in isolation. This knowledge is powerful only when integrated into a comprehensive, multidisciplinary prevention plan.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
⚠ Medication Advisory
Do not discontinue any prescribed medication without consulting your treating physician. Genetic testing does not replace ongoing treatment or surveillance. Always follow your doctor’s recommendations for prostate health.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Acute febrile illness, recent blood transfusion (wait 2 weeks), or active haemolysis.
- Exclusion for Minors: Testing individuals under 18 years is strictly prohibited under UAE Federal Law No. 2 of 2019 and Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Red Flag – Seek Immediate Medical Attention If You Experience: Sudden severe bone pain, acute urinary retention, visible blood in urine, or new neurological deficits (leg weakness). These are not side effects of the test but may indicate advanced disease requiring urgent care.
Patient FAQ & Clinical Guidance
1. What does a positive ELAC2 mutation result mean for my health?
A positive ELAC2 mutation indicates a hereditary predisposition, not a prostate cancer diagnosis, and mandates structured surveillance. It means you carry a gene variant that significantly elevates lifetime prostate cancer risk. Clinical management includes earlier and more frequent PSA screening, possible multiparametric MRI, and discussion of chemoprevention strategies. Genetic counselling will guide you through the exact risk percentages.
2. Can I take this test if I am completely healthy and have no family history?
Yes, individuals seeking proactive health insight may test, but pre‑test counselling is mandatory to interpret incidental findings. Even with a negative family history, a founder mutation could be present. However, results may uncover variants of uncertain significance. Our team provides thorough post‑test discussion to contextualise the findings within your overall risk profile.
3. How is the sample collected and what is the turnaround time?
A certified phlebotomist collects 3–5 mL of whole blood via home visit, and results are ready in 3–4 weeks. You may also submit DNA extracted by a licensed lab or a single drop of blood on an FTA card. The cold‑chain transport preserves sample integrity until NGS analysis begins. The 3–4 week window includes sequencing, bioinformatics alignment, variant annotation, and final clinical interpretation.
UAE Regulatory & Data Privacy Adherence
Legal & Data Protection Framework
- Data Privacy: All genomic data is encrypted and stored within UAE sovereign data centres under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Information Security: Complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Patient Consent: Informed consent obtained in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | ELAC2 Gene Prostate Cancer Susceptibility Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Whole Blood (peripheral, 3-5 mL) or Extracted DNA |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | Z15.03 (Genetic susceptibility to malignant neoplasm of prostate) |
| LOINC Code | 94146-3 (ELAC2 gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians